Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 EN COURS 
Sudden cardiac arrest (SCA) causes ~20% of all deaths in Europe. SCA is lethal within minutes if left untreated and survival rates are presently only 5-20%. Therefore, there is a large medical need to improve SCA prevention and treatment. Designing effective individualized prevention and treatment strategies requires knowledge on genetic and environmental risk factors. So far, these efforts have b ...
Voir le projet

 17

 EN COURS 
The vision of EU-ToxRisk is to drive a paradigm shift in toxicology towards an animal-free, mechanism-based integrated approach to chemical safety assessment. The project will unite all relevant disciplines and stakeholders to establish: i) pragmatic, solid read-across procedures incorporating mechanistic and toxicokinetic knowledge; and ii) ab initio hazard and risk assessment strategies of chemi ...
Voir le projet

 43

 EN COURS 
All chemicals whether they are drugs, cosmetics, agrochemicals or others need to be tested for their safety to man and the environment. The use of whole animal studies for the prediction of adverse effects in man, is problematic due to species dependent effects, high costs and a large burden to animals in terms of numbers and suffering. While there have been major improvements in human in vitro a ...
Voir le projet

 14

 EN COURS 

Blood Biomarker-based Diagnostic Tools for Early Stage Alzheimer’s Disease (BBDiag)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

Alzheimer’s disease (AD) affects more than 7 million people in Europe and this figure is expected to double every 20 years. Despite intensive efforts, no disease-modifying treatments or preventive strategies are available. The lack of specific, sensitive and minimally invasive diagnostics to identify people with early-stage AD to be included in clinical drug intervention trials is among the main r ...
Voir le projet

 13

 EN COURS 
Many therapeutic applications of stem cells require accurate control of their differentiation. To this purpose there is a major ongoing effort in the development of advanced culture substrates to be used as “synthetic niches” for the cells, mimicking the native ones. The goal of this project is to use a synthetic niche cell culture model to test my revolutionary hypothesis that in stem cell differ ...
Voir le projet

 2

 EN COURS 

Secondary prEvention of CardiovascUlaR disease in the Elderly trial (SECURE)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2020,

While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adhe ...
Voir le projet

 13

 TERMINÉ 
"Exposure to secondhand tobacco smoke (SHS) has been classified as a "Group 1" carcinogen (known human carcinogen) by the International Agency for Research on Cancer and has been shown to have adverse health effects on adults and children, including heart disease and respiratory disorders. Electronic cigarettes (e-cigarettes), the most common “electronic nicotine delivery system”, have irrupted i ...
Voir le projet

 11

 TERMINÉ 
Background Biocides not only kill pathogens that are targeted, but can also kill non-pathogens. This can have undesirable side-effects for human health and the environment. Such risks have yet to be sufficiently investigated for most biocides on the EU market because in different environmental compartments (e.g. soil, groundwater and air) active substance ...
Voir le projet

 6

 TERMINÉ 

Coordinated Research Infrastructures Building Enduring Life-science services (CORBEL)

Date du début: 1 sept. 2015, Date de fin: 31 août 2019,

The social and economic challenges of ageing populations and chronic disease can only be met by translation of biomedical discoveries to new, innovative and cost effective treatments. The ESFRI Biological and Medical Research Infrastructures (BMS RI) underpin every step in this process; effectively joining scientific capabilities and shared services will transform the understanding of biological m ...
Voir le projet

 39

 TERMINÉ 

Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2019,

Type 2 diabetes will affect >500 million adults by 2040 and its secondary complications will generate enormous socioeconomic costs - in particular, diabetic kidney disease (DKD), which is already the most common cause of chronic kidney disease. DKD is associated with greatly increased mortality and frequently progresses to end stage renal failure. Pharmacotherapy, dialysis and transplantation repr ...
Voir le projet

 12

 TERMINÉ 

Heart OMics in AGEing (HOMAGE)

Date du début: 1 févr. 2013, Date de fin: 31 janv. 2019,

As more people survive into old age, the prevalence of heart failure (HF), one of the most common and debilitating diseases in older people, will rise still further. Delaying or preventing HF will have great benefit to those at personal risk, their families, society and the economy. HOMAGE aims to provide a biomarker (BM) approach that will a) help identify i. patients at high risk of developing ...
Voir le projet

 22

 TERMINÉ 

Targets and biomarkers for antiepileptogenesis (EPITARGET)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Epilepsy is a devastating condition affecting over 50 million people worldwide. This multidisciplinary project is focused on the process leading to epilepsy, epileptogenesis, in adults. Our main hypothesis is that there are combinations of various causes, acting in parallel and/or in succession, that lead to epileptogenesis and development of seizures. Our central premise and vision is that a comb ...
Voir le projet

 20

 TERMINÉ 
PeptiCaps aims at producing and validating a new family of stimuli-responsive nanocapsules able to encapsulate efficiently and protect specific active ingredients for skin care application. Those nanocapsules will be assembled by nanoemulsion technique using amphiphilic and biocompatible polypeptides diblock copolymers with one hydrophilic poly(ethylene glycol) block and one hydrophobic polypeptid ...
Voir le projet

 10

 TERMINÉ 
"Traumatic brain injury (TBI) is among the leading causes of death and disability and the main cause of death among the under-45s. Most patients with moderate to severe TBI are admitted to intensive care units (ICUs)The “PROSAFE” ICU network was recently established in 6 European countries through EU funding (PHEA 2007331), and has continued to collect high-quality data beyond the grant duration. ...
Voir le projet

 11

 TERMINÉ 

a LOW environmental impact BRAke SYStem (LOWBRASYS)

Date du début: 1 sept. 2015, Date de fin: 31 août 2018,

Primary particulate matter (PM) consists of chemical components suspended in the atmosphere as aerosols, e.g. as a result of exhaust gaseous and friction processes (e.g. braking). Such particles may potentially contribute to smog events in urban areas and might be responsible of negative effects on the environment (e.g. acid rain acidification, toxic effects on plants and animals) and health (e.g. ...
Voir le projet

 12

 TERMINÉ 
Chronic kidney disease (CKD) and acute kidney injury (AKI) are widespread in EU and worldwide, and put substantial burden due to disability, mortality, high cost of treatment, and risk for development of cardiovascular diseases (CVD). Both CKD and AKI are projected to grow due to many factors, including general population aging and increase in diabetes prevalence. Evaluating global and EU regional ...
Voir le projet

 1

 TERMINÉ 

Cementitious Brake Control (LIFE+ COBRA)

Date du début: 1 juil. 2014, Date de fin: 31 mars 2018,

Background Production of fine Particulate Matter (PM) in the road transport sector represents a high risk factor for health. The fine (PM2.5) and ultrafine (PM0.1) particles are particularly hazardous. Despite the efforts invested in reducing GHGs and exhaust emissions, PM limits are widely exceeded across the EU. Brake systems have only recently been th ...
Voir le projet

 4

 TERMINÉ 

European Clinical Research Infrastructures Network - Integrating Activity (ECRIN-IA)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2017,

ECRIN is a distributed ESFRI-roadmap pan-European infrastructure designed to support multinational clinical research, making Europe a single area for clinical studies, taking advantage of its population size to access patients. Servicing multinational trials started during its preparatory phase, and it now applies for an ERIC status by 2011. The ERIC budget will be restricted to core activities re ...
Voir le projet

 48

 TERMINÉ 
Rapidly developing markets such as green construction, energy harvesting and storage, advanced materials for aerospace, electronics, medical implants and environmental remediation are potential key application targets for nanomaterials. There, nanotechnology has the potential to make qualitative improvements or indeed even to enable the technology. Impacts range from increased efficiency of energy ...
Voir le projet

 26

 TERMINÉ 
Patients with diabetes are at risk of developing diabetic nephropathy, which will ultimately result in the requirement for renal replacement therapy and is also associated with high cardiovascular morbidity and mortality. Detection of low concentrations of albuminuria in urine (microalbuminuria) is the current clinical standard for detecting those at significant risk and targeting preventive treat ...
Voir le projet

 21

 TERMINÉ 

Stem-cell based therapy for kidney repair (STELLAR)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,

Chronic kidney disease (CKD) affects 8% of the European population and ultimately results in renal failure due to progressive fibrosis. CDK carries a high mortality risk and the number of affected people rises, increasing the demand on renal replacement therapies while the number of available donor organs stays stable.The STELLAR consortium proposes to develop an alternative to renal replacement ...
Voir le projet

 15

 TERMINÉ 
The management of cardiovascular stability in shock patients is of paramount importance in critical care. New, cutting edge knowledge is necessary to overcome the shortcomings of available therapies, in order to cope with the challenges that anesthesiologists, intensive care specialists and emergency physicians face when dealing with shock patients.Current therapies are targeted to reduce symptoms ...
Voir le projet

 11

 TERMINÉ 
EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts asse ...
Voir le projet

 29

 TERMINÉ 
Background The REACH Regulation (1907/2006/EC) aims to protect human health and the environment, by targeting the movement of substances, on their own, in mixtures or in articles, while enhancing competitiveness and innovation. Its aim is to ensure that goods imported into the EU undergo the same checks as equivalent goods produced within the EU territory ...
Voir le projet

 3

 TERMINÉ 
The consortium led by UKER and EuroHYP, the European Stroke Research Network for Hypothermia, proposes a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke.Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so it ...
Voir le projet

 38

 TERMINÉ 
Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org, 2010).Even modest therapeutic advances that delay disease onse ...
Voir le projet

 17

 TERMINÉ 

Translational research (training) in Polycystic Kidney Disease (TranCYST)

Date du début: 1 déc. 2012, Date de fin: 30 nov. 2016,

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is an inherited kidney disorder with a prevalence of more than 1:1000, characterized by the development of renal cysts, slowly progressing towards end-stage renal disease. ADPKD is often associated with extra-renal complications, which can be devastating. Current therapy is directed towards limiting the morbidity and mortality from these complic ...
Voir le projet

 7

 TERMINÉ 

Promoting the use of in silico methods in industry (LIFE PROSIL)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2016,

Background The EU REACH Regulation promotes a new vision for handling chemical substances. It requires information from manufacturers and/or importers confirming that chemical substances have been evaluated as safe for the intended use. The use of non-animal alternative methods has been foreseen within REACH. In particular, the use of computational mean ...
Voir le projet

 9

 TERMINÉ 
"SEWPROF aims to develop inter-disciplinary and cross-sectoral research capability for the next generation of scientists working in the newly-emerging field of sewage epidemiology. It will provide an integrated approach towards public health monitoring at a community level based on innovative sewage epidemiology techniques. The approach will deliver real-time profiling of community-wide health and ...
Voir le projet

 11

 TERMINÉ 

A Gateway to European Kidney Research Resources - KidneyConnect (KidneyConnect)

Date du début: 1 août 2013, Date de fin: 31 juil. 2016,

Diabetes, Cardiovascular and Chronic kidney (DCC) -diseases are relentlessly increasing globally, causing enormous human suffering, premature deaths and unsustainable costs. Leading European research has indisputably pointed that the kidney filtration barrier and its epithelial cell, the podocyte, is a common denominator for the DCC-diseases. However, European excellence and expertise have remaine ...
Voir le projet

 19

 TERMINÉ 
Background Environmental and health problems related to endocrine disruption have increased in recent decades. Abnormalities in the reproductive system of various aquatic species (fish, molluscs, amphibians, reptiles) as well as human fertility have been linked to chemical pollution threats. Key aims of the EU’s REACH Regulation include improving awar ...
Voir le projet

 4

 TERMINÉ 
Cancer cachexia is a life-threatening syndrome characterized by severe body weight loss, due to depletion of adipose tissue and skeletal muscle, and affects up to 80% of patients with advanced cancers. The rapid loss of muscle mass is the main cause of function impairment, fatigue and respiratory complications, leading to death in 20-48% of cases. To date, no effective treatment is available. By u ...
Voir le projet

 2

 TERMINÉ 
"For chronic kidney diseases there is little chance that the vast majority of the world¿s population will have access to renal replacement therapy with dialysis. There is yet no adequate alternative with curative intent than allo-transplantation. This approach is seriously impaired by eventually limited graft survival and by the scarce availability of donors. We propose an innovative strategy that ...
Voir le projet

 1

 TERMINÉ 
Amyotrophic Lateral Sclerosis is one of the most devastating diseases in neurology affecting in Europe 50,000 individuals at any time, and causing around 10,000 deaths each year. ALS is characterized by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS affects otherwise healthy people at any time in adulthood. The patient becomes paralyzed and dies ...
Voir le projet

 16

 TERMINÉ 
"Nanotechnology is rapidly expanding. However, some types of engineered nanoparticles can be toxic for living organisms and exhibit negative impact on the environment. Thus, the design of new nanomaterials must be supported by a rigorous risk analysis. Following the recommendations by the EU REACH system and regarding ethical aspects, the risk assessment procedures should be performed with possibl ...
Voir le projet

 5

 TERMINÉ 
"The aim of TINN2 is to evaluate azithromycin, included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. Azithromycin is a macrolid antibiotic with anti-inflammatory properties active against Ureaplasma. It might be effective in reducing the severity of bronhopulmonary disease in which Ureaplasma infection and inflammation play a r ...
Voir le projet

 17

 TERMINÉ 
ToxBank establishes a dedicated web-based warehouse for toxicity data management and modelling, a ‘gold standards’ compound database and repository of selected test compounds, and a reference resource for cells, cell lines and tissues of relevance for in vitro systemic toxicity research carried out across the FP7 HEALTH.2010.4.2.9 Alternative Testing Strategies SEURAT program. The project develops ...
Voir le projet

 10

 TERMINÉ 
PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision bef ...
Voir le projet

 38

 TERMINÉ 

Predictive toxicology of engineered nanoparticles (PRENANOTOX)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2015,

The production of many consumer products based on manufactured NanoParticles (NPs) has led to a growing public and regulatory concern about the safety of nanomaterials. Since experimental toxicological testing of NPs, especially in vivo animal studies is costly and time-consuming, it is necessary to develop a novel research field and associated methods and tools to reach the goal of predictive nan ...
Voir le projet

 3

 TERMINÉ 
The aim of TINN is to evaluate ciprofloxacin, fluconazole and micafungin in neonates; two anti-infectious drugs included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. These drugs are prescribed off-label to treat neonatal infections that are life threatening situations and associated with long-term complications. In order to val ...
Voir le projet

 16